Penumbra to Present at 44th Annual J.P. Morgan Healthcare Conference
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: PRnewswire
- Conference Presentation: Penumbra, Inc. is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026, at 6:45 PM ET, showcasing its latest advancements in thrombectomy technology.
- Webcast Availability: The presentation will be accessible via a webcast on the company's website under the 'Investors' tab, ensuring that the information remains available for at least two weeks post-event for investor convenience.
- Company Overview: As the world's leading thrombectomy company, Penumbra focuses on developing innovative technologies to address challenging medical conditions such as ischemic stroke and venous thromboembolism, aiming to improve patient outcomes and quality of life.
- Global Reach: Penumbra's product portfolio, which includes computer-assisted vacuum thrombectomy, is utilized in over 100 countries, highlighting its significant presence and influence in the global healthcare market.
PEN
$314.89+Infinity%1D
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for PEN is 307.92 USD with a low forecast of 266.00 USD and a high forecast of 355.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
13 Analyst Rating
10 Buy
3 Hold
0 Sell
Strong Buy
Current: 316.970
Low
266.00
Averages
307.92
High
355.00
Current: 316.970
Low
266.00
Averages
307.92
High
355.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
